Trial Outcomes & Findings for In Situ Caries Model of Fluoride Toothpastes (NCT NCT01005966)
NCT ID: NCT01005966
Last Updated: 2013-07-29
Results Overview
SMH recovery test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Difference in percent SMH recovery was calculated by comparing study NaF toothpaste (1426ppmF) with reference AmF toothpaste (1400ppmF).
COMPLETED
PHASE3
65 participants
Baseline to 14 days
2013-07-29
Participant Flow
Participants were recruited at the clinical site.
83 participants were screened and 18 participants did not meet the study criteria thus 65 participants were enrolled into the study. The subjects were randomized to receive all 5 study treatments in a pre-determined computerized randomised order as per a typical cross-over design.
Participant milestones
| Measure |
Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]
Study toothpaste containing sodium fluoride/ silica (1426ppm fluoride as NaF)
|
Amine Fluoride(AmF) Toothpaste (1400ppmF)
Reference toothpaste containing amine fluoride (1400ppm fluoride as AmF)
|
Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)
Reference toothpaste containing sodium monofluorophosphate and sodium fluoride (1450ppmF - 1000ppmF as NaMFP and 450ppmF as NaF)
|
NaF Toothpaste (675ppmF)
Study toothpaste containing sodium fluoride and silica (675ppmF as NaF)
|
Placebo Toothpaste (0ppmF)
Placebo fluoride free toothpaste
|
|---|---|---|---|---|---|
|
Treatment Period 1 (14 Days)
STARTED
|
13
|
13
|
13
|
13
|
13
|
|
Treatment Period 1 (14 Days)
COMPLETED
|
11
|
13
|
12
|
13
|
13
|
|
Treatment Period 1 (14 Days)
NOT COMPLETED
|
2
|
0
|
1
|
0
|
0
|
|
Washout Period 1 (4 Days)
STARTED
|
11
|
13
|
12
|
13
|
13
|
|
Washout Period 1 (4 Days)
COMPLETED
|
11
|
13
|
12
|
12
|
13
|
|
Washout Period 1 (4 Days)
NOT COMPLETED
|
0
|
0
|
0
|
1
|
0
|
|
Treatment Period 2 (14 Days)
STARTED
|
13
|
13
|
12
|
12
|
11
|
|
Treatment Period 2 (14 Days)
COMPLETED
|
13
|
12
|
10
|
11
|
11
|
|
Treatment Period 2 (14 Days)
NOT COMPLETED
|
0
|
1
|
2
|
1
|
0
|
|
Washout Period 2 (4 Days)
STARTED
|
13
|
12
|
10
|
11
|
11
|
|
Washout Period 2 (4 Days)
COMPLETED
|
13
|
12
|
10
|
11
|
11
|
|
Washout Period 2 (4 Days)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
|
Treatment Period 3 (14 Days)
STARTED
|
12
|
8
|
12
|
13
|
12
|
|
Treatment Period 3 (14 Days)
COMPLETED
|
12
|
7
|
12
|
13
|
11
|
|
Treatment Period 3 (14 Days)
NOT COMPLETED
|
0
|
1
|
0
|
0
|
1
|
|
Washout Period 3 ( 4 Days)
STARTED
|
12
|
7
|
12
|
13
|
11
|
|
Washout Period 3 ( 4 Days)
COMPLETED
|
12
|
7
|
12
|
13
|
11
|
|
Washout Period 3 ( 4 Days)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
|
Treatment Period 4 (14 Days)
STARTED
|
10
|
11
|
11
|
10
|
13
|
|
Treatment Period 4 (14 Days)
COMPLETED
|
10
|
10
|
11
|
10
|
12
|
|
Treatment Period 4 (14 Days)
NOT COMPLETED
|
0
|
1
|
0
|
0
|
1
|
|
Washout Period 4 (4 Days)
STARTED
|
10
|
10
|
11
|
10
|
12
|
|
Washout Period 4 (4 Days)
COMPLETED
|
10
|
10
|
11
|
10
|
12
|
|
Washout Period 4 (4 Days)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
|
Treatment Period 5 (14 Days)
STARTED
|
9
|
12
|
11
|
11
|
10
|
|
Treatment Period 5 (14 Days)
COMPLETED
|
9
|
12
|
11
|
11
|
10
|
|
Treatment Period 5 (14 Days)
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
| Measure |
Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F]
Study toothpaste containing sodium fluoride/ silica (1426ppm fluoride as NaF)
|
Amine Fluoride(AmF) Toothpaste (1400ppmF)
Reference toothpaste containing amine fluoride (1400ppm fluoride as AmF)
|
Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)
Reference toothpaste containing sodium monofluorophosphate and sodium fluoride (1450ppmF - 1000ppmF as NaMFP and 450ppmF as NaF)
|
NaF Toothpaste (675ppmF)
Study toothpaste containing sodium fluoride and silica (675ppmF as NaF)
|
Placebo Toothpaste (0ppmF)
Placebo fluoride free toothpaste
|
|---|---|---|---|---|---|
|
Treatment Period 1 (14 Days)
Adverse Event
|
1
|
0
|
0
|
0
|
0
|
|
Treatment Period 1 (14 Days)
Protocol Violation
|
1
|
0
|
1
|
0
|
0
|
|
Washout Period 1 (4 Days)
Withdrawal by Subject
|
0
|
0
|
0
|
1
|
0
|
|
Treatment Period 2 (14 Days)
Adverse Event
|
0
|
1
|
1
|
0
|
0
|
|
Treatment Period 2 (14 Days)
Protocol Violation
|
0
|
0
|
0
|
1
|
0
|
|
Treatment Period 2 (14 Days)
Withdrawal by Subject
|
0
|
0
|
1
|
0
|
0
|
|
Treatment Period 3 (14 Days)
Protocol Violation
|
0
|
1
|
0
|
0
|
1
|
|
Treatment Period 4 (14 Days)
Protocol Violation
|
0
|
1
|
0
|
0
|
0
|
|
Treatment Period 4 (14 Days)
Other Reason
|
0
|
0
|
0
|
0
|
1
|
Baseline Characteristics
In Situ Caries Model of Fluoride Toothpastes
Baseline characteristics by cohort
| Measure |
All Randomized Participants
n=65 Participants
All randomized participants who received at least one dose of the study treatments or who have been evaluated for AEs were included.
|
|---|---|
|
Age Continuous
|
67.0 years
STANDARD_DEVIATION 9.97 • n=5 Participants
|
|
Sex: Female, Male
Female
|
41 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
24 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
65 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Baseline to 14 daysPopulation: Per protocol (PP) population: All randomized participants who received at least one dose of the study treatments and provided at least one measurement SMH. Participants without any major protocol violations in given study treatment period were included in the PP population.
SMH recovery test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Difference in percent SMH recovery was calculated by comparing study NaF toothpaste (1426ppmF) with reference AmF toothpaste (1400ppmF).
Outcome measures
| Measure |
NaF Toothpaste (1426ppmF)
n=56 Participants
Study toothpaste containing NaF/ silica (1426ppmF)
|
AmF Toothpaste (1400ppmF)
n=57 Participants
Reference toothpaste containing AmF (1400ppmF)
|
NaMFP/NaF Toothpaste (1450ppmF)
Reference toothpaste containing NaMFP/NaF (1450ppmF- 1000ppmF as NaMFP and 450ppmF as NaF)
|
NaF Toothpaste (675ppmF)
Toothpaste containing NaF/silica (675ppmF)
|
Placebo Toothpaste (0ppmF)
Placebo - fluoride free toothpaste
|
|---|---|---|---|---|---|
|
Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF)
|
38.05 Percentage SMHR
Standard Error 2.52
|
41.06 Percentage SMHR
Standard Error 2.53
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline to 14 daysPopulation: PP population: All randomized participants who received at least one dose of the study treatments or provided at least one measurement SMH. Participants without any major protocol violations in given study treatment period were included in the PP population.
SMH test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Differences in percent SMH recovery due to study and reference toothpastes were calculated.
Outcome measures
| Measure |
NaF Toothpaste (1426ppmF)
n=56 Participants
Study toothpaste containing NaF/ silica (1426ppmF)
|
AmF Toothpaste (1400ppmF)
n=57 Participants
Reference toothpaste containing AmF (1400ppmF)
|
NaMFP/NaF Toothpaste (1450ppmF)
n=58 Participants
Reference toothpaste containing NaMFP/NaF (1450ppmF- 1000ppmF as NaMFP and 450ppmF as NaF)
|
NaF Toothpaste (675ppmF)
n=59 Participants
Toothpaste containing NaF/silica (675ppmF)
|
Placebo Toothpaste (0ppmF)
n=59 Participants
Placebo - fluoride free toothpaste
|
|---|---|---|---|---|---|
|
Percent SMH Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste (1400ppm F) and Placebo (0ppmF)
|
38.05 Percentage SMHR
Standard Error 2.52
|
41.06 Percentage SMHR
Standard Error 2.53
|
33.48 Percentage SMHR
Standard Error 2.49
|
29.08 Percentage SMHR
Standard Error 2.50
|
14.49 Percentage SMHR
Standard Error 2.48
|
SECONDARY outcome
Timeframe: Baseline to 14 daysPopulation: PP population: All randomized participants who received at least one dose of the study treatments or provided at least one significant measurement of fluoride uptake. Participants without any major protocol violations in given study treatment period were included in the PP population.
Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.
Outcome measures
| Measure |
NaF Toothpaste (1426ppmF)
n=56 Participants
Study toothpaste containing NaF/ silica (1426ppmF)
|
AmF Toothpaste (1400ppmF)
n=57 Participants
Reference toothpaste containing AmF (1400ppmF)
|
NaMFP/NaF Toothpaste (1450ppmF)
n=58 Participants
Reference toothpaste containing NaMFP/NaF (1450ppmF- 1000ppmF as NaMFP and 450ppmF as NaF)
|
NaF Toothpaste (675ppmF)
n=59 Participants
Toothpaste containing NaF/silica (675ppmF)
|
Placebo Toothpaste (0ppmF)
n=59 Participants
Placebo - fluoride free toothpaste
|
|---|---|---|---|---|---|
|
Change From Baseline in Enamel Fluoride Uptake Potential
|
2342.35 micrograms (μg)* F/centimeters(cm)^2
Standard Error 123.65
|
2305.11 micrograms (μg)* F/centimeters(cm)^2
Standard Error 123.83
|
1809.74 micrograms (μg)* F/centimeters(cm)^2
Standard Error 121.83
|
1649.44 micrograms (μg)* F/centimeters(cm)^2
Standard Error 121.93
|
462.95 micrograms (μg)* F/centimeters(cm)^2
Standard Error 120.92
|
Adverse Events
NaF Toothpaste (1426ppmF)
AmF Toothpaste (1400ppmF)
NaMFP/ NaF Toothpaste (1450ppmF)
NaF Toothpaste (675ppmF)
Placebo Toothpaste (0ppmF)
Overall
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
NaF Toothpaste (1426ppmF)
n=57 participants at risk
Study toothpaste containing NaF/ silica (1426ppmF)
|
AmF Toothpaste (1400ppmF)
n=57 participants at risk
Reference toothpaste containing AmF (1400ppmF)
|
NaMFP/ NaF Toothpaste (1450ppmF)
n=59 participants at risk
Reference toothpaste containing NaMFP/ NaF (1450ppmF - 1000ppmF as NaMFP and 450ppmF as NaF)
|
NaF Toothpaste (675ppmF)
n=59 participants at risk
Toothpaste containing NaF/ silica (675ppmF)
|
Placebo Toothpaste (0ppmF)
n=59 participants at risk
Placebo: fluoride free toothpaste
|
Overall
n=65 participants at risk
|
|---|---|---|---|---|---|---|
|
Infections and infestations
Nasopharyngitis
|
1.8%
1/57 • Number of events 1 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
|
8.8%
5/57 • Number of events 5 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
|
0.00%
0/59 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
|
5.1%
3/59 • Number of events 3 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
|
3.4%
2/59 • Number of events 2 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
|
15.4%
10/65 • Number of events 11 • All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.
|
Additional Information
GSK Response Center
GlaxoSmithKline
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER